Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT03513497 |
Other study ID # |
18-0291 |
Secondary ID |
1K01DE027087-01 |
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
October 18, 2018 |
Est. completion date |
June 28, 2023 |
Study information
Verified date |
June 2023 |
Source |
University of North Carolina, Chapel Hill |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
To characterize the expression of IFI16 and AIM2 in gingival tissues in an inflammatory
response using an acrylic mouthguard (also referred to as a stent) induced bacteria
overgrowth method.
Participants: A maximum of 72 Adult subjects will be recruited from the patients, students
and staff at the University of North Carolina, as well as the general population in or near
Chapel Hill NC.
Procedures (methods):
Medical history, demographics, (height/weight), urine based pregnancy test, vital signs (to
include blood pressures, and pulse) standard dental clinical measures (to include plaque
index, gingival index, bleeding on probing, and clinical attachment level), alginate
impressions taken for fabrication of an acrylic stent (mouthguard), 2 gingival biopsies, 2
subgingival (below the gumline) plaque samples, and Scaling Root planing (SRP)/or adult
prophylaxis
Description:
A total of 72 subjects will be enrolled. Specifically, a sufficient number of adults 18 years
and older will be screened until 36 healthy (PPC-A) subjects and 36 subjects with severe
periodontal disease (PPC-G) will be enrolled. Eligibility for study participation will be
determined during the screening session. Barring dropout, subject participation will include
1 to 8 visits lasting over a maximum period of 42 days. The last 3 visits (visit 5-8) will
depend on the individual need of the subject for providing SRP. Clinical data and medical
history data will be collected at the screening visit to ascertain eligibility. All subjects
will have dental plaque and a gingival biopsy collected at baseline. Enrolled subjects will
be included in an experimental gingivitis model Stent-Induced Biofilm Overgrowth (SIBO) for
21 days. Individuals will return for safety checks every week during the 21-day period. At
21-days, plaque samples and a gingival biopsy will be collected. For diseased individuals SRP
will initiate during the 21-day visit at the SIBO quadrant. Visit 6 (28 days) will include
the post-biopsy follow up, prophylaxis (for healthy individuals) and SRP (diseased
individuals). Subjects receiving SRP may have 2 additional visits (visit 7 at day 35 and
visit 8 at day 42) for completing the SRP of all quadrants and will be dependent on
individual need. Medical histories, demographics, height and weight, clinical and biological
data described above will be recorded and stored on a secure server located at the University
of North Carolina. Each participant enrolled into the study will have a unique identification
number that has been stripped of any information that could be used by non-study members to
identify the subject.